Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v7-FR Version v2-FR
Language French French
Date Updated 2020-08-26 2020-06-26
Drug Identification Number 02182866 02182866
Brand name DALACIN C 300 MG DALACIN C 300 MG
Common or Proper name DALACIN C 300MG DALACIN C 300MG
Company Name PFIZER CANADA ULC PFIZER CANADA ULC
Ingredients CLINDAMYCIN CLINDAMYCIN
Strength(s) 300MG 300MG
Dosage form(s) CAPSULE CAPSULE
Route of administration ORAL ORAL ORAL ORAL
Packaging size 100 BTL 100 BTL
ATC code J01FF J01FF
ATC description MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2020-06-30 2020-06-30
Estimated end date Unknown
Actual end date 2020-08-25
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments
Health Canada comments